A cough and cold medication that is commonly used to treat cold, flu, allergy, body aches, fever, and respiratory tract infection symptoms. Eases breathing difficulties and discomfort caused by a blocked nose, sinusitis, and upper respiratory tract infections. A potent therapeutic agent that is commonly used to relieve pain and fever in cold and flu conditions. (G.G.G. de Oliveira, 2017) Constricts blood vessels in the nasal passages, leading to reduced swelling and congestion. Relieves symptoms of allergic conditions such as rhinitis, as well as nasal discomfort caused by colds and flu. (G.G.G. de Oliveira, 2017) Offers quick relief from sinus congestion and pressure, addressing symptoms associated with nasal congestion due to various respiratory conditions. (Jaqueline Livier Castillo, 2023) Offers a comprehensive treatment for the symptomatic relief of colds, flu, and allergies. Provides relief from nasal congestion and sinus pressure, and clears nasal passages for easier breathing. Effectively manages allergic reactions by blocking the action of histamine, a substance in the body responsible for causing allergy symptoms.

A broad-spectrum antibiotic that has good antimicrobial activity against aerobic gram-positive and gram-negative bacteria. (Arijit Ghosh, 2012) Exerts higher cure rates (95.6%) compared with other oral third-generation cephalosporins. (Arijit Ghosh, 2012) Has potent antibacterial activity against the major bacterial pathogens involved in lower respiratory tract infections. (Geddes, 1991) A safe and useful agent in the therapy of skin and soft tissue infections. (K J Tack, 1991) Demonstrates a higher eradication rate of pathogens (97.6%) in the skin and soft tissue infections. (K J Tack, 1991) A valuable addition to the antibacterial available for the treatment of infections of the lower respiratory tract. (A M Geddes, 1991) A better-tolerated medicine that is associated with better compliance than penicillin-based regimens. (J A Balfour P. B., 1996) An efficacious molecule as parenterally administered ceftriaxone for the treatment of bronchopneumonia in hospitalized individuals. (J E Frampton, 1992) Shows greater clinical efficacy [97.2%] than co-amoxidav [94.7%] in the treatment of acute exacerbations of chronic bronchitis. (P. Periti, 1990)

A synthetic progesterone used to treat various gynecological and reproductive health conditions. An effective, safe and clinically beneficial drug for patients with dysmenorrhea. (Fuminori Taniguchi, 2019) Demonstrates beneficial effects in women with amenorrhea, oligomenorrhea, dysfunctional uterine bleeding and irregular menstrual cycles. ( 2009) A trusted option for women trying to conceive and prevent bleeding disorders. (Jo Kitawaki, 2021) Helps maintain a regular menstrual cycle, minimizes excessive bleeding, relieves period pain, and prevents the return of irregular cycles. (Nilesh Trivedi, 2016) Highly effective in regulating the menstrual cycle and alleviating menstrual pain. (Natalia Podzolkova, 2016) Supports pregnancy by reducing the risk of miscarriage in women with threatened miscarriage. (Carp, 2012) A preferred choice that offers superior oral bioavailability over oral micronized progesterone. (Chao Peng, 2021) Effectively relieves endometriosis symptoms, reduces lesion size and improves fertility in patients with endometriosis-related infertility. (Chao Peng, 2021) The superior choice for women seeking fertility treatment, long-term endometriosis management, and hormone therapy. (Chao Peng, 2021)

Atorvastatin is a lipid-lowering medication (statin). It works by blocking an enzyme (HMG-CoA-reductase) that is required in the body to make cholesterol. It thus lowers "bad" cholesterol (LDL), triglycerides and raises "good" cholesterol (HDL).

An anti-hypertensive drug that lowers blood pressure and helps prevent strokes, heart attacks, and kidney problems. Provides better long-term compliance and better blood pressure control than enalapril. (J Amerena, 2002) A beneficial therapeutic option in the management of patients with hypertension. (M Sharpe, 2001) An effective and well-tolerated agent in the treatment of mild-to-moderate hypertension, producing sustained 24-hour blood pressure control. (J Mallion, 1999) More effective than atenolol 50 mg in lowering systolic blood pressure in patients with mild-to-moderate hypertension. (L Alcocer, 2004) More effective than losartan in reducing seated systolic blood pressure (22.1 vs. 16.5 mmHg) and standing systolic blood pressure (21.0 vs. 16.3 mmHg). (Y T Lee, 2004) Provides superior control of BP than losartan and has no association with increased risk of adverse events. (Gui-Lin Xi, 2008) A promising drug for controlling hypertension and reducing vascular risk in high-risk elderly patients with new-onset diabetes. (Jugdutt, 2010) Produces a greater reduction reduce BP than valsartan therapy in patients with hypertension. (Hisato Takagi & Group, 2013) A good candidate for blood pressure control in patients with essential hypertension and comorbid conditions such as diabetes, metabolic syndrome, dyslipidemia, or renal disease. (Mohammed Yunus Khan, 2021) More effective antihypertensive treatment than ramipril 10 mg in patients with mild-to-moderate hypertension. (Yves Lacourcière, 2006)

A single-pill combination of an angiotensin receptor blocker and cardioselective β blocker for the treatment of uncontrolled hypertension. Widens blood vessels to lower blood pressure, improves blood flow, and decreases the workload on the heart. Offers greater and more consistent systolic and diastolic BP lowering over the 24-hour period. (Asmar, 2012) An effective drug in reducing blood pressure and achieving the blood pressure target. (A Prem Kumar, 2021) Provides a full 24-hour BP coverage, particularly protecting against the BP rise characterizing early morning hours. (Guido Grassi, 2008) Displays large and sustained reductions of blood pressure in patients with hypertension. (Domenico Galzerano, 2010) Reducing cardiovascular events and mortality in patients with hypertension and coronary heart diseases. (Dimitris P Papadopoulos, 2009) A promising drug that diminishes cardiovascular risk in high-risk patients. (Philippe R Akhrass, 2011) A beneficial therapeutic choice in the management of patients with hypertension. (M Sharpe, 2001)

A potent loop diuretic that treats edema due to chronic heart failure, renal failure, and cirrhosis. Effectively reduces excess fluid levels in the body and treats swelling associated with heart, liver, kidney, or lung disease. (M Young, 2001) Induces a significant decrease in blood pressure and reversion of peripheral edema in patients with chronic renal failure. (D Russo, 1990) An effective diuretic for diseases related to edema. (H Kido, 2001) More effective than 40 mg furosemide in reducing edema, pulmonary congestion and improving symptoms of congestive heart failure. (Goebel, 1993) An effective agent in inducing loss of body weight and increasing sodium excretion in patients with congestive heart failure. (Kramer, 1994) A high-ceiling loop diuretic is useful for correcting extracellular fluid volume expansion in patients with chronic renal failure. (D Russo, 1990) Eight times more potent than furosemide in patients with edema. (A Herchuelz, 1988) Represents a reasonable alternative to conventional diuretic management in patients with essential hypertension. (Luft, 1993) Displays a rapid onset of action in patients with edema. (J Broekhuysen, 1986) A safe and well-tolerated medicament for chronic heart failure patients. (Juan Cosín, 2002)

An anti-diabetic class of medicine that is used in the management of type 2 diabetes mellitus. An effective therapeutic choice for patients inadequately controlled on sulfonylurea or Metformin alone. (Anil Pareek, 2013) The preferred choice in hypertensive patients with diabetes for optimal blood glucose control. (Rakesh Kumar Sahay, 2020) A suitable combinational drug for early as well as long-standing diabetes. (Rakesh Kumar Sahay, 2020) Reduces pill burden and provides effective glycemic control in type 2 diabetic patients. (Sudhir Tripathi, 2019) A potential agent that provides greater adherence to therapy and improves glycemic control. (Sudhir Tripathi, 2019) Stimulates pancreatic β cells to release insulin and reduces blood sugar. (Abdul Basit M. R., 2012) An effective drug that controls hyperglycemia in people with T2DM. (Sudhir Tripathi, 2019) Effectively reduces fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels. (Abdul Basit, 2012) Significantly more effective in controlling blood glucose levels in type 2 diabetic patients inadequately controlled by metformin alone. (G Charpentier, 2001) A potential agent that achieves good glycemic control with a better tolerability profile. (Anil Pareek, 2013) A preferential option for most type 2 diabetes mellitus patients who have not achieved adequate control with monotherapy. (JM. Amate, 2015) An effective and well-tolerated antidiabetic drug that provides an important treatment option for managing type 2 diabetes. (Massi-Benedetti, 2003)

A triple combination of glimepiride, metformin, and voglibose that treats high blood sugar in type 2 diabetes. A highly effective and safe triad in controlling all the glycemic parameters like HbA1c, FPG, and PPHG for optimal management of type 2 diabetes. (A. A. FARUQUI, 2015) A good therapeutic option for the management of uncontrolled glycemia who is having poor glycemic control. (A. A. FARUQUI, 2015) An effective drug in reducing the risk of weight gain in patients with type 2 diabetes and alleviates the risk of developing co-morbidities associated with weight gain such as obesity and dyslipidemia. (A. A. FARUQUI, 2015) A promising treatment option for the clinical management of Type 2 diabetes. (A. A. FARUQUI, 2015) Potentially ameliorates glycemic control and reduces further microvascular and cardiovascular complications. (Ashok K. Das, 2022) Improves insulin sensitivity and reduces postprandial blood glucose by regulating glucose absorption. (Mathew John, 2015)

An antiepileptic medication that works in the brain to prevent and control seizures. A first-line agent in the management of partial and tonic-clonic epilepsy. (S M Grant, 1992) More efficacious in the treatment of negative symptoms than valproate in patients with mood and schizoaffective disorder. (Michele Raja, 2003) An effective and well-tolerated agent in refractory bipolar disorder and schizoaffective disorder. (Wetid Pratoomsri, 2005) An appropriate alternative to antipsychotic and antidepressant medications for treating psychiatric symptoms in children and adolescents. (Kyle Morrow, 2021) Significantly more effective and with better tolerability than carbamazepine as an add-on strategy treatment in bipolar patients. (M F Juruena, 2009) A valuable option in the treatment of childhood epilepsy. (Lynne Bang, 2003) An appropriate substitute for carbamazepine for the treatment of partial seizures in patients who are unable to tolerate carbamazepine. (M M Kalis, 2001) A preferable alternative treatment to phenytoin, particularly for individuals with focal onset seizures. (Sarah J Nevitt, 2018)

An antidepressant that is used to treat various mental health conditions by balancing serotonin levels in the brain. It helps in improving mood, reducing anxiety, and enhancing overall mental well-being. A potent selective serotonin reuptake inhibitor for the treatment of depression, obsessive-compulsive disorder, panic disorder and social phobia. (Bourin, 2003) Effectively reduces the number of panic attacks and prevents relapse. (D Dunner, 1998) Offers an effective therapy for a broad spectrum of psychiatric disorders. (D Dunner, 1998) 4An effective and well-tolerated treatment for major depressive disorder in elderly patients, including those with chronic depression. (Mark Hyman Rapaport, 2003) A first-choice medication for depression and anxiety disorders due to proven efficacy & safety. (Antona J Wagstaff, 2002) An excellent first-line treatment for depression, anxiety disorders, OCD, and panic disorder. (N S Gunasekara, 1998) Offers long-term benefits in preventing relapse or recurrence of depression (up to 1 year). (N S Gunasekara, 1998) An effective, well-tolerated treatment for patients with social phobia. (D Baldwin, 1999) Displays a more rapid onset of action than clomipramine in reducing the number of panic attacks. (Y Lecrubier, 1997)

An antiepileptic drug is prescribed for managing neuropathic pain (nerve pain). An efficacious agent in the treatment of painful diabetic neuropathy and postherpetic neuralgia. (M Kamp-Jensen, 2001) An effective and safe drug for treating neuropathic pain. (M A Laird, 2000) The preferred first-line treatment for managing neuropathic pain. (Funda Levendoglu, 2004) Lessens both the intensity and frequency of neuropathic pain in patients with spinal cord injuries. (Funda Levendoglu, 2004) Demonstrates effectiveness in treating a range of painful neuropathic conditions. (M A Mellegers, 2001) An important addition to the management of neuropathic pain syndromes. (Nicholson, 2000) A well-tolerated and effective treatment for managing the pain associated with postherpetic neuralgia. (Bruce Parsons, 2004)

Belongs to a group of medicines called antibiotics that treats various bacterial infections. Clavulanic acid decreases bacterial resistance and enhances the activity of cefuroxime against the bacteria. Demonstrates antibacterial activity against all the pathogens usually responsible for ear, nose, and throat infections. (Westphal, 1990) An effective treatment in patients with upper and lower respiratory tract infections. (L J Scott, 2001) An efficacious agent in patients with acute bronchitis or acute exacerbations of chronic bronchitis. (Lesley J. Scott, 2001) Produces clinical response rates (cure or improvement) range from 66 to 94% in lower respiratory tract infections. (Lesley J. Scott, 2001) A well-tolerated medication in children and adults with various bacterial infections. (Lesley J. Scott, 2001) An effective alternative treatment to conventional regimens, with the potential for better compliance. (S Mehra, 1998) A safe and effective antimicrobial for the treatment of pneumonia in adults. (B G Yangco, 1990)

A broad-spectrum antibiotic that has good antimicrobial activity against aerobic gram-positive and gram-negative bacteria. (Arijit Ghosh, 2012) Clavulanic Acid is a beta-lactamase inhibitor which reduces resistance and enhances the activity of Cefpodoxime against bacteria. An effective antibiotic for the treatment of acute exacerbations of chronic bronchitis. (P Periti, 1990) Exerts higher cure rates (95.6%) compared with other oral third-generation cephalosporins. (Arijit Ghosh, 2012) A valuable addition to the antibacterial available for the treatment of infections of the lower respiratory tract. (A M Geddes, 1991) Has potent antibacterial activity against the major bacterial pathogens involved in lower respiratory tract infections. (Geddes, 1991) A safe and useful agent in the therapy of skin and soft tissue infections. (K J Tack, 1991) A better-tolerated medicine that is associated with better compliance than penicillin-based regimens. (J A Balfour P. B., 1996)

A proton pump inhibitor that decreases the amount of acid in the stomach. (Dr L. Laine, 2002) Significantly improves the frequency and severity of all gastroesophageal reflux disease symptoms. (R. Jones, 2008) More potent acid inhibitor than other currently available proton pump inhibitors. (B.-S. Sheu, 2005) Maintains intragastric pH above 4 for a longer duration than omeprazole 40mg. (R. Jones T. P., 2008) A safe and effective treatment of chronic heartburn in patients without erosive oesophagitis. (Dr P. O. Katz, 2003) A well-tolerated agent with a strong gastric acid suppression effect. (Jocelyn Zhou, 2016) Provides a faster healing and higher healing rate than lansoprazole 30 mg in erosive esophagitis patients. (M. B. Fennerty, 2005)

An azole antifungal medication that has broad-spectrum fungistatic activity against yeasts and fungi. (F Montero-Gei, 1993) Disrupts the synthesis of ergosterol, which is an essential building block in fungal cell membranes. (C. Charlier, 2006) Provides over 90% clinical cure or improvement for cutaneous mycosis including tinea, pityriasis, cryptococcosis, and candidiasis. (D Debruyne, 1997) A first-line treatment option in several cases of invasive candidiasis. (C Charlier, 2006) An efficacious and safe regimen in the treatment of tinea corporis and cruris. (Stary A., 1998) An effective treatment against a wide range of fungi and has a favorable pharmacokinetic profile. (J H Dobloug, 1992) A promising therapy for the treatment of cryptococcal meningitis. (E M Bailey, 1990) An important antifungal drug in the management of fungal infections in patients with immune deficiencies. (K L Goa, 1995) A highly effective agent in urinary tract infections caused by Candida species and other fungi. (M S Saag, 1988) A mycological effective drug for the treatment of tinea corporis and tinea cruris. (J Faergemann, 1997) A useful antifungal agent for the treatment of systemic deep-seated mycoses. (Hideo Ikemoto, 1989) As effective as posaconazole, and itraconazole in preventing invasive fungal infections in pediatric patients. (M Döring, 2015)

A type of vitamin B9, also known as folate or folic acid, helps the body to make healthy new red blood cells. An essential nutrient for the proper functioning of the brain, synthesis, repair of DNA and other genetic material. (James A Greenberg, 2011) Essential for cell growth and development during pregnancy, fetal development, and adolescence. Has FDA approval for the treatment of megaloblastic and macrocytic anemias due to folic deficiency. (Merrell & John P. McMurry) Has the potential to reduce the risks of preterm birth, heart irregularities, and cleft palate during pregnancy. Provides substantial benefits in reducing the risk of neural tube defects such as spina bifida and anencephaly in the developing fetus. (Kirsten Bibbins-Domingo, 2017)

An antibiotic medication that treats a wide range of bacterial infections. (N J Leggett, 1990) Possesses broad-spectrum activity against all gram-positive and negative pathogenic bacteria and atypical organisms. (Danni Ramdhani, 2021) Encourages the growth of beneficial bacteria in the stomach that aid in digestion. A beneficial drug that decreases the risk of diarrhea caused due to antibiotics, and infections. An effective and well-tolerated antibiotic for the treatment of upper urinary tract infections. (L Weissbach, 1990) A viable therapeutic choice for acute uncomplicated urinary tract infections as compared to amoxycillin or co-trimoxazole. (R N Brogden, 1989) Offers the additional benefit of covering beta-lactamase-producing strains of bacteria that are resistant to many penicillins. (D R Edelstein, 1993)